Price:
Rs. 2,120.00
Sample Type: EXTRA PULMONARY
Fasting Not Required
Notes: A0093
Frequently Asked Questions (FAQ's):
What is the AFB MDR Screen by Hain LPA, Extra Pulmonary Test?
This test uses the Hain Line Probe Assay to detect Mycobacterium tuberculosis DNA and mutations associated with resistance to rifampicin and isoniazid in extrapulmonary samples.
Why is this test important?
It helps identify multidrug-resistant TB (MDR-TB) in extrapulmonary sites, allowing early modification of treatment regimens and improving patient outcomes.
Who should undergo this test?
Patients with suspected extrapulmonary TB or those not responding to standard TB treatment are advised to undergo this test.
How is the test performed?
DNA is extracted from the extrapulmonary sample and analyzed using the Hain Line Probe Assay at Metropolis Healthcare to identify drug-resistance mutations.
What do the results indicate?
Results indicate whether the Mycobacterium tuberculosis strain is resistant or sensitive to rifampicin and isoniazid, guiding effective treatment planning.
Are there any risks associated with the test?
The test is safe, with only minimal procedural risk associated with extrapulmonary sample collection.
Why choose Metropolis Healthcare for this test?
Metropolis Healthcare provides rapid, accurate, and reliable MDR-TB detection using advanced Hain LPA technology with expert molecular analysis for precise and effective patient management.